---

---

therapeutics   entities : Nabriva therapeutics plc   

save search

---

Antimicrobial Resistance Market to Reach $9.5 Billion, Globally, by 2032 at 7.6% CAGR: Allied Market Research
Published: 2023-09-14 (Crawled : 06:00) - prnewswire.com
NBRVF | $0.0002 -50.0% 330 |

n/a

| -99.95% | O: 18.58% H: 3.92% C: 3.92%
reach research market

---

Global MRSA Drugs Markets, 2017-2022, 2022-2027F, 2032F: Focus on Lipopeptides, Oxazolidinones, Cephalosporin, Tetracycline, Folate Antagonist, & Lipoglycopeptide
Published: 2023-09-08 (Crawled : 17:00) - prnewswire.com
AZNCF | $138.24 -4.19% 800 |

Health Technology

| 0.46% | O: 0.86% H: 0.0% C: -0.1%
IPIX | $0.0101 92.86% 230K |

Manufacturing

| -40.48% | O: 0.0% H: 1.19% C: 0.6%
ABBV | News | $166.41 1.06% 0.0% 5.5M |

Health Technology

| 10.91% | O: 0.07% H: 0.0% C: 0.0%
CPIX | $1.65 6.02% 790 |

Health Technology

| -6.59% | O: -2.99% H: 0.0% C: 0.0%
AZN | $68.56 0.29% 0.29% 4.7M |

Health Technology

| 0.39% | O: 0.49% H: 0.24% C: -0.16%
global

---

Delisting of Securities of Nymox Pharmaceutical Corporation; Aridis Pharmaceuticals Inc.; Novan, Inc.; ViewRay, Inc.; 9 Meters Biopharma, Inc.; Nabriva Therapeutics plc; UTA Acquisition Corporation; AppHarvest, Inc.; Yellow Corporation; Proterra Inc.; Amyris, Inc.; Chain Bridge I; LatAmGrowth SPAC; and SpringBig Holdings, Inc. from The Nasdaq Stock Market
Published: 2023-09-07 (Crawled : 20:00) - globenewswire.com
AMRSQ | $0.0015 -95.0% 21K |

Manufacturing

| -91.11% | O: -10.0% H: 16.05% C: 8.64%
VRAYQ | $0.0001 0.0% 600 |

Manufacturing

| -99.99% | O: 6.84% H: 13.6% C: -4.0%
NDAQ | $60.35 0.47% 0.46% 3.1M |

Finance

| 16.16% | O: 0.0% H: 0.19% C: -0.45%
ARDS | $0.0615 2.82% 410K |

Health Technology

| -31.03% | O: 0.0% H: 13.45% C: -12.07%
nasdaq acquisition pharmaceuticals therapeutics proterra market

---

Arbutus Appoints Two New Executives
Published: 2023-07-10 (Crawled : 20:00) - globenewswire.com
BMY | $48.93 1.3% 0.0% 10M |

Health Technology

| -22.7% | O: -0.26% H: 0.96% C: 0.75%
NBRV | $1.42 1.39% 720K |

Health Technology

| -8.46% | O: 1.85% H: 0.0% C: -4.11%
KRYS | $158.63 -3.26% -3.37% 340K |

Health Technology

| 37.53% | O: -0.4% H: 0.11% C: -0.1%
ABUS | News | $2.725 -0.18% -0.18% 930K |

Health Technology

| 21.68% | O: 2.65% H: 0.0% C: -2.16%

---

Nabriva Therapeutics Adjourns Extraordinary General Meeting of Shareholders
Published: 2022-01-14 (Crawled : 14:20) - globenewswire.com
NBRV | $1.42 1.39% 720K |

Health Technology

| Email alert Add to watchlist
meeting therapeutics

---

Nabriva Therapeutics Adjourns Extraordinary General Meeting of Shareholders on January 18, 2022
Published: 2022-01-18 (Crawled : 14:20) - globenewswire.com
NBRV | $1.42 1.39% 720K |

Health Technology

| 178.7% | O: 2.06% H: 0.0% C: -3.65%
meeting therapeutics

---

Nabriva Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Published: 2022-03-01 (Crawled : 14:20) - globenewswire.com
NBRV | $1.42 1.39% 720K |

Health Technology

| 212.78% | O: -2.05% H: 3.44% C: -0.13%
nasdaq grant therapeutics

---

Nabriva Therapeutics Announces First Patient Enrolled in Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic Fibrosis
Published: 2022-04-11 (Crawled : 14:20) - globenewswire.com
NBRV | $1.42 1.39% 720K |

Health Technology

| 276.76% | O: 2.95% H: 0.0% C: -4.66%
xenleta fibrosis trial therapeutics

---

Nabriva Extends Exclusive Agreement to Promote and Distribute SIVEXTRO® (tedizolid phosphate) in the U.S. Through the End of 2026
Published: 2022-05-05 (Crawled : 14:20) - globenewswire.com
NBRV | $1.42 1.39% 720K |

Health Technology

| 365.42% | O: 3.21% H: 0.16% C: -7.97%
sivextro agreement

---

Nabriva Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update
Published: 2022-05-05 (Crawled : 14:20) - globenewswire.com
NBRV | $1.42 1.39% 720K |

Health Technology

| 389.99% | O: -0.62% H: 2.4% C: -9.76%
update therapeutics financial results

---

Nabriva Therapeutics Expands XENLETA® (lefamulin) Presence with Exclusive Agreement with Er-Kim Pharmaceuticals
Published: 2022-07-18 (Crawled : 14:20) - globenewswire.com
NBRV | $1.42 1.39% 720K |

Health Technology

| -69.99% | O: 16.22% H: 0.59% C: -14.41%
xenleta pharmaceuticals therapeutics agreement

---

Nabriva Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update
Published: 2022-08-03 (Crawled : 14:20) - globenewswire.com
NBRV | $1.42 1.39% 720K |

Health Technology

| -71.17% | O: -1.52% H: 0.0% C: -6.65%
update therapeutics financial results

---

Nabriva Therapeutics Completes Patient Enrollment in Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic Fibrosis
Published: 2022-08-11 (Crawled : 14:20) - globenewswire.com
NBRV | $1.42 1.39% 720K |

Health Technology

| -70.11% | O: 2.74% H: 10.14% C: -0.87%
xenleta fibrosis trial therapeutics

---

Nabriva Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
Published: 2022-09-06 (Crawled : 14:20) - globenewswire.com
NBRV | $1.42 1.39% 720K |

Health Technology

| -65.26% | O: 2.08% H: 0.0% C: -6.17%
conference global therapeutics

---

Nabriva Therapeutics Announces Date of 1-for-25 Reverse Stock Split
Published: 2022-09-15 (Crawled : 14:20) - globenewswire.com
NBRV | $1.42 1.39% 720K |

Health Technology

| -70.09% | O: 52.24% H: 16.91% C: -7.61%
therapeutics

---

Nabriva Therapeutics Pivoting Strategic Focus Reports Third Quarter Financial Results and Provides Corporate Update
Published: 2022-11-10 (Crawled : 14:20) - globenewswire.com
NBRV | $1.42 1.39% 720K |

Health Technology

| -34.87% | O: 0.91% H: 7.27% C: 5.0%
update therapeutics financial results

---

Global Antibiotics Market Report 2022 to 2027: Industry Trends, Share, Size, Growth, Opportunities and Forecasts
Published: 2023-01-23 (Crawled : 12:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K |

Health Technology

| -5.02% | O: 0.93% H: 0.0% C: 0.0%
JNJ | News | $147.91 1.49% -0.03% 9.6M |

Health Technology

| -14.1% | O: 0.21% H: 0.31% C: -0.47%
GSK | $39.75 1.22% 0.0% 1.6M |

Health Technology

| 11.93% | O: -0.06% H: 0.49% C: 0.0%
ABBV | News | $166.41 1.06% 0.0% 5.5M |

Health Technology

| 10.41% | O: 0.18% H: 0.38% C: -0.87%
SNY | News | $46.32 2.05% 2.01% 3.3M |

Health Technology

| -7.31% | O: -0.51% H: 0.0% C: 0.0%
NBRV | $1.42 1.39% 720K |

Health Technology

| -8.39% | O: 0.0% H: 1.29% C: -0.23%
antibiotics global report market

---

Nabriva Therapeutics Provides Corporate Update
Published: 2023-01-06 (Crawled : 12:20) - globenewswire.com
NBRV | $1.42 1.39% 720K |

Health Technology

| -39.75% | O: -32.96% H: 1.27% C: -17.72%
therapeutics update

---

Nabriva Therapeutics Announces Positive Topline Results from Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic Fibrosis
Published: 2022-11-28 (Crawled : 12:20) - globenewswire.com
NBRV | $1.42 1.39% 720K |

Health Technology

| -34.56% | O: 5.53% H: 25.33% C: -9.17%
xenleta fibrosis topline trial therapeutics positive results cystic fibrosis phase 1

---

Nabriva Therapeutics to Report Third Quarter 2022 Financial Results and Recent Corporate Highlights on November 10, 2022
Published: 2022-11-07 (Crawled : 12:20) - globenewswire.com
NBRV | $1.42 1.39% 720K |

Health Technology

| -36.58% | O: -1.75% H: 8.18% C: 4.35%
report therapeutics financial results

---

Gainers vs Losers

67%

33%

Top 10 Gainers

AGBA | News | $1.26 215.0% 68.25% 130M |

Finance

EGOX | $0.0515 43.06% 30.1% 330M |

OLB 4 | $0.33 -14.95% 25.53% 840K |

Technology Services

NVFY | $2.77 31.28% 23.83% 33M |

Consumer Durables

ZCMD | $1.87 28.97% 22.46% 31M |

Commercial Services

RCON | $0.1112 13.01% 21.28% 1.7M |

Distribution Services

INSG | $3.03 25.21% 20.13% 330K |

Electronic Technology

GCTK | $0.8191 22.25% 18.2% 190K |

Manufacturing

WLGS | News | $0.59 18.0% 17.9% 2.3M |

ASNS | $0.828 21.75% 17.86% 18K |

---

Your saved searches

---